Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc is preparing for a first-in-human PRP study in up to 50 advanced cancer patients with solid tumors.

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) approved a reverse stock split anticipated to take effect at market open on October 26, 2026.

The 1-for-10 consolidation will automatically combine every 10 outstanding common shares into one share. Propanc said the action is intended to restore compliance with Nasdaq’s continued listing standards, including its $1.00 minimum bid price requirement, and support future growth plans. The company is preparing for a Phase 1b first-in-human study of PRP in up to 50 advanced cancer patients with solid tumors in the first quarter of 2027.

1 point · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Minor point. Forward-looking: it has not happened yet and may not happen.PRP development plans include a Phase 1b first-in-human study in up to 50 patients in the first quarter of 2027.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.1-for-10 reverse split is intended to restore Nasdaq compliance, including the $1.00 minimum bid price requirement.

Argus 15 min delay 5 alerts

-12.43% vs previous close $0.28 last price 1.9x rel. volume Open Argus

Details

Market move: PPCB -12.43% vs previous close. 1-for-10 reverse stock split

$0.28 – $0.33 Day Range

$2.72M Mkt Cap at Last Price

On Oct 22, the day this news came out, the latest delayed price for PPCB is 12.43% below the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $0.28. Relative volume is above average at 1.9x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Reverse stock split ratio: 1-for-10 Anticipated effective date: October 26, 2026 Minimum bid price requirement: $1.00

Reverse stock split ratio

1-for-10

Approved by the board

Anticipated effective date

October 26, 2026

Expected effective at market open

Minimum bid price requirement

$1.00

Nasdaq continued-listing compliance rationale stated in the article

Key Terms

reverse stock split, cusip, first-in-human

3 terms

reverse stock split financial

"approved a 1-for-10 reverse stock split of the Company’s issued and outstanding shares"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

cusip technical

"with a new CUSIP number, 74346N883"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

first-in-human medical

"Phase 1b, First-In-Human (FIH) study"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (“Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of the open of the market October 26, 2026.

As a result of the Reverse Stock Split, every 10 pre-split shares of Company common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 10,331,116 million shares (as of October 8, 2026) to approximately 1,033,112 million shares on a pro forma basis. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis (per participant basis at DTC). The Reverse Stock Split will not affect the par value of the Company’s common stock.

The Company anticipates that the effective time of the Reverse Stock Split will be before market open on October 19, 2026, with the common stock trading on a post-split basis under the Company’s existing trading symbol, “PPCB,” with a new CUSIP number, 74346N883. Securities Transfer Corporation, the Company’s transfer agent, will act as the exchange agent for the Reverse Stock Split.

“The Reverse Stock Split is being implemented to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market and Nasdaq’s $1.00 minimum bid price requirement and support future growth plans,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We are excited about the advancement of our lead asset, PRP, as we prepare for our Phase 1b, First-In-Human (FIH) study, in up to 50 advanced cancer patients with solid tumors in the first quarter of 2027. By undertaking this important corporate action, we will clear the pathway for execution of future R&D milestone events that we believe will be transformative for the Company and its shareholders.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Propanc Biopharma’s reverse stock split expected to take effect, and what is the ratio?

The 1-for-10 reverse stock split is anticipated to take effect at market open on October 26, 2026. Every 10 outstanding common shares will automatically combine into one share.

Do PPCB shareholders need to act, and how will fractional shares be handled?

Shareholders do not need to take action for the automatic share consolidation. Fractional shares will be rounded up to the nearest whole share on a per-shareholder basis, or a per-participant basis at DTC.